Intravenous infusion of ferric carboxymaltose can cause a transient hypophosphatemia.

Clinical findings:

(1) recent intravenous infusion of ferric carboxymaltose

(2) serum phosphorus < 2.0 mg/dL with nadir about 2 weeks after the infusion

(3) return to normal phosphorus concentrations in 4-6 weeks


Often the patient is asymptomatic but symptoms can develop after high or repeated doses.


Findings in severe cases may include:

(1) fatigue

(2) muscle cramps

(3) osteomalacia

To read more or access our algorithms and calculators, please log in or register.